| Methods | Multicentre, randomized, double‐blind, clinical trial |
| Participants | Aged 40 to 70 years, stage 1 hypertension (140 mmHg to 159 mmHg/90 mmHg to 99 mmHg; > 130 mmHg in people with diabetes); no more than 1 antihypertensive, no previous coronary heart disease and severe chronic disease Country: Brazil |
| Interventions | Monotherapy: losartan starting dose 50 mg, up to 100 mg daily. Combination therapy: chlorthalidone 12.5 mg + amiloride 2.5 mg starting dose up to chlorthalidone 25 mg + amiloride 5 mg daily Amlodipine up to 10 mg daily and propranolol up to 160 mg daily, in an open fashion, will be added if blood pressure is not controlled. |
| Outcomes | Primary: blood pressure variation and proportion of use of add‐on drugs, adverse events, development or worsening of microalbuminuria and left ventricular hypertrophy on electrocardiogram Secondary: fatal or major cardiovascular events: myocardial infarction, stroke, coronary interventions, heart failure, duplication of creatinine. Time frame: 18 months. |
| Notes | Number of participants naïve to antihypertensive drugs not reported. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.